Compare SII & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | WGS |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2011 | 2020 |
| Metric | SII | WGS |
|---|---|---|
| Price | $119.61 | $72.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $133.30 | $90.44 |
| AVG Volume (30 Days) | 89.1K | ★ 645.5K |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | $32.78 | $12.70 |
| Revenue Next Year | N/A | $24.31 |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $78.79 | $32.21 |
| 52 Week High | $169.63 | $170.87 |
| Indicator | SII | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 36.98 |
| Support Level | $113.08 | $71.85 |
| Resistance Level | $120.13 | $94.82 |
| Average True Range (ATR) | 4.13 | 6.64 |
| MACD | -1.52 | -3.00 |
| Stochastic Oscillator | 0.21 | 4.57 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.